Nyxoah has appointed Liam Kelly as Chief Executive Officer, effective October 1, 2026, succeeding Olivier Taelman as the medical technology company increases its focus on commercialization in the United States.
The leadership transition follows FDA approval and the U.S. launch of Nyxoah’s Genio system, a leadless and battery-free hypoglossal neurostimulation therapy for obstructive sleep apnea.
Nyxoah said Kelly’s appointment reflects its evolution into a more U.S.-focused commercial organization as it works to increase physician adoption and broaden use of Genio.
Kelly brings more than 25 years of leadership experience in the medical technology industry. He most recently served as Chairman, President and CEO of Teleflex until January 2026.
Kelly became Teleflex’s President and CEO in January 2018 and Chairman of its board in May 2020. He originally joined Teleflex in 2009 and held several senior positions before becoming CEO, including President of EMEA, President of International, President of the Americas and Chief Operating Officer.
Before joining Teleflex, Kelly spent approximately 10 years in senior management positions at Hill-Rom Holdings. He currently serves as a director of Enovis and holds a Bachelor of Business Studies degree from the University of Limerick.
Nyxoah is focused on developing and commercializing treatments for obstructive sleep apnea through neuromodulation. Its Genio system received European CE Mark approval in 2019 and later received an expanded European indication covering Complete Concentric Collapse patients.
The company completed an IPO on Euronext Brussels in September 2020 and a Nasdaq listing in July 2021.
Following positive results from Nyxoah’s DREAM IDE pivotal study in 2024, Genio received FDA approval in August 2025. The company is now in the early stages of building its commercial presence in the U.S., which it views as a central part of its growth strategy.
KEY QUOTES:
“Nyxoah is entering a new chapter, with the United States at the center of our growth strategy. We are very pleased to welcome Liam as our new CEO. He is a seasoned U.S. MedTech executive with a strong track record of scaling organizations, driving commercial performance and creating shareholder value. On behalf of the Board, I also want to thank Olivier for his leadership over the past seven years and his contribution in bringing Nyxoah from clinical development through FDA approval and into U.S. commercialization.”
Robert Taub, Chairman of Nyxoah
“I am incredibly excited to join Nyxoah at this pivotal stage. Genio is a truly differentiated technology in the treatment of sleep apnea. The technology has tremendous potential to impact patient lives globally. The U.S. launch is still in its early stages, and the momentum we’re seeing in physician adoption gives me great confidence in what lies ahead. Drawing on my experience at Teleflex building and scaling global businesses, I look forward to working with the Nyxoah team to scale the business and bring Genio to many more OSA patients.”
Liam Kelly, Chief Executive Officer of Nyxoah
